射频消融治疗孤立性自主功能性甲状腺结节:拉丁美洲多中心研究
这项回顾性、观察性、多中心队列研究纳入81例经组织学证实为良性的孤立性自主功能性甲状腺结节患者,接受单次射频消融治疗。随访期间结节体积缩小率中位数持续增加,甲状腺功能亢进缓解率为93.8%(76/81),总体并发症发生率为6.2%(5/81),结论认为射频消融是 promising 的治疗选择。
要点
- 射频消融后12个月结节体积缩小率中位数为-90.2%,甲亢缓解率为93.8%(76/81)。
- 58.02%(47/81)患者在1个月内促甲状腺激素水平恢复正常,3个月时另有33.3%(27/81)达到正常。
- 6个月随访时体积缩小率≥50%与甲亢缓解相关;总体并发症发生率为6.2%(5/81)。
核心结论
- 这项多中心研究结果提示,射频消融是孤立性自主功能性甲状腺结节患者的一种有前景的治疗选择,无论其基线特征(包括体积、年龄或组成)如何。
- 干预的临床成功可能与6个月时的体积缩小率有关。
研究设计与样本
- 回顾性、观察性、多中心队列研究,纳入81例经组织学证实为良性且接受单次射频消融治疗的孤立性自主功能性甲状腺结节患者。
- 分析内容包括患者人口学特征、结节超声特征、每次随访时的甲状腺功能谱、评估临床症状以确定是否达到甲状腺功能正常状态,以及结节体积缩小测量。
- 进行双变量分析以识别这些变量与甲亢缓解之间的关联。
主要发现
- 随访期间体积缩小率中位数持续增加,1、3、6和12个月时分别为-50%、-74.9%、-78.4%和-90.2%。
- 甲亢缓解率为93.8%(76/81)。
- 射频消融术后,58.02%(47/81)患者在1个月随访内促甲状腺激素水平恢复正常,到3个月时另有33.3%(27/81)达到正常。
- 基线体积≥10、20或30 mL不影响临床成功的达成。
- 双变量分析中,6个月随访时体积缩小率≥50%与甲亢缓解相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Autonomously functioning thyroid nodules (AFTNs) represent ∼5% of all thyroid nodules and often necessitate definitive treatments such as surgery or radioiodine (131I), both of which have inherent risks. Radiofrequency ablation (RFA) has emerged as an effective and safe therapeutic option for managing AFTNs. This study aims to assess the effectiveness and safety of RFA for solitary AFTNs in various countries across Latin America. Methods: This retrospective, observational, multicenter cohort study included patients with a solitary AFTN that was histologically confirmed as benign and treated with a single session of RFA. The study included an analysis of patient demographics, sonographic characteristics of the nodules, thyroid profile assessment at each follow-up visit, evaluation of clinical symptoms to determine the achievement of a euthyroid state, and the measurement of nodule volume reduction. In addition, a bivariate analysis was conducted to identify associations between these variables and the resolution of hyperthyroidism. Results: Our study enrolled 81 patients with a solitary, benign AFTN. The volume reduction ratio (VRR) consistently increased over the follow-up period, with medians of -50%, -74.9%, -78.4%, and -90.2% at 1, 3, 6, and 12 months, respectively. The rate of resolution of hyperthyroidism was 93.8% (76/81). Following the RFA procedure, 58.02% of patients (47/81) normalized their thyrotropin levels within 1 month of follow-up, and by 3 months, an additional 33.3% had achieved normalization (27/81). Notably, a baseline volume ≥10, 20, or 30 mL did not affect the achievement of clinical success. In bivariate analyses, a VRR ≥50% at the 6-month follow-up was associated with the resolution of hyperthyroidism. Overall complications occurred in 6.2% of patients (5/81), including 1.2% (1/81) of a major complication (transient Horner syndrome), 3.7% cases of transient dysphonia (3/81), and 1.2% (1/81) of hypothyroidism requiring low-dose levothyroxine replacement. Conclusions: The results of this multicenter study suggest that RFA is a promising treatment option for patients with solitary AFTN, regardless of their baseline characteristics, including volume, age, or composition. The clinical success of the intervention may be related to the VRR at 6 months.
引用
- Dueñas JP, Buitrago-Gómez N, Rahal A, et al. Radiofrequency Ablation for Solitary Autonomously Functioning Thyroid Nodules: Multicenter Study from Latin America. Thyroid. 2024. PMID: 39699644. doi:10.1089/thy.2024.0338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。